BTAI - CIK 0001720893
The table below shows BioXcel Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$57.62M | -$72.03M | -$155.01M | -$135.34M | -$82.15M | -$66.35M |
| Capital expenditure | $0.00 | $0.00 | $20.00K | $139.00K | $445.00K | $316.00K |
| Investing cash flow | $0.00 | $0.00 | -$20.00K | -$139.00K | -$445.00K | -$316.00K |
| Dividends paid | - | - | - | - | - |
BioXcel Therapeutics, Inc. reported operating cash flow of -$57.62M for fiscal year 2025. That is up 20.0% from -$72.03M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$2.20M (FY 2017) to -$57.62M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | $9.02M |
| Financing cash flow | $56.52M | $36.66M | $26.52M | $96.24M | $102.45M | $247.36M |